Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/36157

Type
Article
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

IMPACT OF PREEXISTING DENGUE IMMUNITY ON ZIKA VIRUS EMERGENCE IN A DENGUE ENDEMIC REGION
Rodriguez-Barraquer, Isabel et al. | Date Issued: 2019
Author
Rodriguez-Barraquer, Isabel
Costa, Federico
Nascimento, Eduardo J. M.
Nery, Nivison
Castanha, Priscila M. S.
Sacramento, Gielson Almeida
Cruz, Jaqueline
Carvalho, Mayara
Olivera, Daiana de
Hagan, José E.
Adhikarla, Haritha
Wunder, Elsio A.
Coêlho, Danilo F.
Azar, Sasha R.
Rossi, Shannan L.
Vasilakis, Nikos
Weaver, Scott C.
Ribeiro, Guilherme S.
Balmaseda, Angel
Harris, Eva
Nogueira, Maurício L.
Reis, Mitermayer G.
Marques, Ernesto T. A.
Cummings, Derek A. T.
Ko, Albert I.
Affilliation
University of California. Department of Medicine. San Francisco, CA, USA.
Universidade Federal da Bahia. Instituto da Saúde Coletiva. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.
University of Pittsburgh. Department of Infectious Disease and Microbiology. Pittsburgh, PA, USA.
Universidade Federal da Bahia. Instituto da Saúde Coletiva. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil / Universidade de Pernambuco. Faculdade de Ciências Médicas. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.
Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil / Universidade Federal de Pernambuco. Departamento de Química Fundamental. Recife, PE, Brasil.
University of Texas Medical Branch. Institute for Translational Science. Galveston, TX, USA.
University of Texas Medical Branch. Department of Microbiology and Immunology. Galveston, TX, USA.
University of Texas Medical Branch. Department of Pathology. Galveston, TX, USA.
University of Texas Medical Branch. Department of Microbiology and Immunology. Galveston, TX, USA.
Universidade Federal da Bahia. Instituto da Saúde Coletiva. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil.
Sustainable Sciences Institute. Managua, Nicaragua / Ministry of Health. Centro Nacional de Diagnóstico y Referencia. Laboratorio Nacional de Virología. Managua, Nicaragua.
University of California. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, CA, USA.
Faculdade de Medicina de São José do Rio Preto. São Jose do Rio Preto, SP, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil.
University of Pittsburgh. Department of Infectious Disease and Microbiology. Pittsburgh, PA, USA / Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil / University of Pittsburgh. Graduate School of Public Health. Pittsburgh, PA, USA.
University of Florida. Department of Biology. Gainesville, FL, USA / University of Florida. Emerging Pathogens Institute. Gainesville, FL, USA.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.
Abstract
The clinical outcomes associated with Zika virus (ZIKV) in the Americas have been well documented, but other aspects of the pandemic, such as attack rates and risk factors, are poorly understood. We prospectively followed a cohort of 1453 urban residents in Salvador, Brazil, and, using an assay that measured immunoglobulin G3 (IgG3) responses against ZIKV NS1 antigen, we estimated that 73% of individuals were infected during the 2015 outbreak. Attack rates were spatially heterogeneous, varying by a factor of 3 within a community spanning 0.17 square kilometers. Preexisting high antibody titers to dengue virus were associated with reduced risk of ZIKV infection and symptoms. The landscape of ZIKV immunity that now exists may affect the risk for future transmission.
DeCS
Adolescente
Adulto
Anticorpos Antivirais / sangue
Número Básico de Reprodução
Brasil
Criança
Reações Cruzadas
Dengue / imunologia
Surtos de Doenças
Feminino
Humanos
Imunoglobulina G / sangue
Masculino
Estudos Prospectivos
Estudos Soroepidemiológicos
População Urbana
Proteínas não Estruturais Virais / imunologia
Adulto Jovem
Zika virus
Infecção por Zika virus / imunologia
 
Citation
RODRIGUEZ-BARRAQUER, Isabel et al. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science, v. 363, n. 6427, p. 607-610, 8 Feb. 2019.
DOI
10.1126/science.aav6618
ISSN
0036-8075